Durata Therapeutics sales and marketing update

Durata launched Dalvance dalbavancin in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The wholesale acquisition cost (WAC) for Dalvance is $4,470 for a recommended 2-dose regimen consisting of 1,000 mg followed one week later by 500 mg. FDA approved the product in May. According to the agency, Dalvance is the first drug with Qualified Infectious Disease Product (QIDP) designation to receive FDA approval. The designation qualifies Dalvance for an additional five years of market exclusivity (see BioCentury, May 26). ...